Tuesday, August 04, 2020
Follow us on
मेरा परिवार समृद्घ परिवार के तहत परिवार पहचान पत्र बनेगा सुख का आधार: डॉ बनवारी लालऐसा लगता है कि बैकल-स्टैब्लिंग बजाज और ड्यूलो को बचाने के लिए सिटिचक्ट एक्ट में बदलाव करना होगा:सुनील जाखड़बिकरू कांड: SC के रिटायर जज के नेतृत्व में तीन सदस्यीय जांच आयोग कानपुर पहुंचाकेरल में भारी बारिश की संभावना, कई जिलों में ऑरेंज और येलो अलर्ट जारीमेरा परिवार-समृद्घ परिवार विषय के अंतर्गत परिवार पहचान पत्र बनेगा सुविधाओं और सूचनातंत्र का मजबूत आधार:असीम गोयलहरियाणा के मुख्यमंत्री मनोहर लाल ने प्रदेश में परिवार पहचान पत्र कार्यक्रम का किया शुभारम्भलखनऊ: आज CM आवास में मनाई जाएगी दीपावली, सीएम योगी करेंगे शुभारंभराम मंदिर के भूमि पूजन पर अमेरिका में खास तैयारी, सभी मंदिरों में होगी पूजा

No necessary process will be skipped: ICMR

July 05, 2020 05:48 AM


No necessary process will be skipped: ICMR

Medical staff screen residents in Mumbai. Pratik Chorge/HT Photo
Sanchita Sharma


New Delhi : The Indian Council of Medical Research (ICMR) said on Saturday that its attempt to speed up the development of a potential coronavirus disease (Covid-19) vaccine was aimed at cutting red tape, a remark that came after its plan of a mid-August launch invited condemnation from experts for setting an impractical target not in line with rigorous scientific standards.

Experts said the premier biomedical research body’s clarification on Saturday that the move was meant to cut red tape did not address how the accelerated timeline could be achieved. It appeared unrealistic even by the best global standards and involved potential risks, they said.

ICMR said on Friday it was attempting to launch the world’s first Covid-19 vaccine on August 15, triggering disbelief in the scientific community. The plan was disclosed in a letter by ICMR to 12 institutes where human trials are to be held for the vaccine, Covaxin, ordering them to secure necessary approvals from internal committees and recruit people for clinical tests by July 7 with a warning that “non-compliance will be viewed very seriously”.

The vaccine has been jointly developed by ICMR and Hyderabad-based Bharat Biotech (BBIL), with the latter itself previously indicating that a vaccine could take more time. In a report on Wednesday, Bharat Biotech chairman and managing director Krishna Ella said that if clinical trials of Covaxin met safety and efficacy standards, the vaccine could be available for mass use by early 2021.

On Saturday, ICMR said: “The letter by DG-ICMR to investigators of the clinical trial sites was meant to cut unnecessary red tape, without bypassing any necessary process, and speed up recruitment of participants... ICMR is committed to treat the safety and interest of people of India as a topmost priority.” This statement mentioned neither the August 15 deadline, nor the July 7 one .

The statement followed widespread condemnation for ICMR for appearing to abandon clinical trial safeguards and putting the lives and safety of people at risk in its rush to produce an indigenous vaccine by Independence Day, a feat that is impossible if scientific protocols for trial and data review are followed.

In the letter, dated July 2, ICMR director general Dr Balram Bhargava said, “ln view of the public health emergency due to Covid-19 pandemic and urgency to launch the vaccine, you are strictly advised to fast track all approvals related to initiation of the clinical trial and ensure that the subject enrolment is initiated no later than 7 July 2020. Kindly note that non-compliance will be viewed very seriously,” said the ICMR-DG.

In the statement issued on Saturday, the apex research organisation said: “ICMR’s process is exactly in accordance with the globally accepted norms to fast-track the vaccine development for diseases of pandemic potential wherein human and animal trials can continue in parallel.” “Our trials will be done following the best practices and rigour, and will be reviewed, as required, by a Data Safety Monitoring Board... ICMR is committed to treat the safety and interest of people as a topmost priority,” it said.

Bharat Biotech chairman Krishna Ella, who was copied on Dr Bhargava’s letter, declined to comment on ICMR’s timeline of clinical trials. Bharat Biotech is among seven Indian firms working on Covid vaccines and was the first to get the regulatory nod to begin Phase 1 and Phase 2 human trials on Monday.

Trials for vaccines can take several years. Several countries have allowed the development processes to be fast-tracked to tackle the unprecedented health emergency but even the leading efforts are estimated to conclude the development process only by the end of the year.

Experts say ICMR’s timeline for Covaxin is scientifically implausible even by the global fast-tracked standards, as the vaccine is yet to begin human clinical trials. Globally, 18 experimental Covid-19 vaccines are in various phases of human trials.

“There is no sensible scientific way that makes it possible to announce that a potential vaccine will be ready without three months of phases 1 and 2 trial data to indicate whether it will work at all. Even with fast-tracking and planning phase 3 trial in anticipation of the first two phases being successful, the trial can begin only after data from the first two trials is analysed and certified, which takes at least three months. You need at least six months for preliminary data on how effective and safe the vaccine is,” asked Dr T Jacob John, virologist and former professor at the Christian Medical College, Vellore, Tamil Nadu.

A researcher, who works with the government and did not wish to be named, said: “Science depends on clinical outcomes; it doesn’t follow deadlines. The definitive language in the letter is problematic.”

ICMR’s Saturday letter had a response to such criticism too. “...the best of India’s medical professionals and research scientists should not be second guessed for their professionalism or adherence to the highest scientific rigour.”

Dr Bhargava did not respond to repeated calls and text messages seeking

Have something to say? Post your comment